Thermo Fisher Posts Profit-to-Profit Gains on Revenue, Operating Income, Net Income and Diluted EPS in Interim Filing

Bottom line

Thermo Fisher Scientific Inc. closed an interim reporting window on a profit-to-profit footing on every income-statement line the filing discloses for both the three-month and six-month views. Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period reached $11,994,000,000 USD, higher than the prior-year comparative of $10,855,000,000 USD for the three months ended June 28, 2025. Revenue for the six-month year-to-date period came in at $22,999,000,000 USD, also higher than the $21,219,000,000 USD reported for the six months ended June 28, 2025. Operating Income (Loss) followed the same shape: $2,087,000,000 USD for the three-month window versus $1,834,000,000 USD a year earlier, and $3,950,000,000 USD for the six months ended June 27, 2026 versus $3,551,000,000 USD for the six months ended June 28, 2025, with both current and prior periods showing an operating profit. Net Income (Loss) Attributable to Parent registered $1,736,000,000 USD for the quarter and $3,387,000,000 USD for the half year, each higher than the prior-year profit of $1,617,000,000 USD and $3,124,000,000 USD respectively, and both retained the prior period's profit classification. Earnings Per Share, Diluted tracked the same direction: $4.68 per diluted share USD/SHARES for the three months ended June 27, 2026 against $4.28 per diluted share USD/SHARES for the three months ended June 28, 2025, and $9.10 per diluted share USD/SHARES for the six months ended June 27, 2026 against $8.26 per diluted share USD/SHARES for the six months ended June 28, 2025, with both readings sitting in positive territory.

The filing's identity is established by 10-Q for period-ended-2026-06-27, filed by THERMO FISHER SCIENTIFIC INC. (ticker TMO, CIK 0000097745) under accession 0000097745-26-000144. Source scope is limited to the unaudited condensed consolidated financial statements and accompanying notes contained in that filing, anchored by Note 1 on the Nature of Operations and Summary of Significant Accounting Policies and the balance-sheet detail that feeds into Note 2 and the borrowings disclosure in Note 3. Subsequent-disclosure items — the legal proceedings commentary under Item 1 and Item 1A, the risk-factor and equity-activity references under Item 2, the market-risk and controls discussion under Item 3 and Item 4, and the exhibit index tied to Item 5, Item 6 and Note 6 — are in scope for source breadth but contribute no incremental income-statement figures here. Fair-value hierarchy detail referenced through Level 1, Level 2 and Level 3, together with the long-term borrowings disclosure in Note 4, is available as supporting context but does not alter the headline results.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. Readers cross-checking this profit-to-profit pattern against a recent peer filing can compare the shape against Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and ONEOK Posts Higher Revenue, Operating Income, Net Income and Diluted EPS Year-Over-Year in Interim Filing to see how the same directional pattern appears across different issuers.

Financial performance

- Top-line scale moved higher on both windows versus the prior-year comparatives. Revenue from Contract with Customer, Excluding Assessed Tax was $11,994,000,000 USD for the three months ended June 27, 2026 and $22,999,000,000 USD for the six months ended June 27, 2026, compared with $10,855,000,000 USD for the three months ended June 28, 2025 and $21,219,000,000 USD for the six months ended June 28, 2025. The authorized direction is higher than the prior period on both the three-month and six-month year-to-date windows, leaving the year-over-year comparison uniformly constructive.

- Operating profitability tracked the revenue line. Operating Income (Loss) was $2,087,000,000 USD for the three months ended June 27, 2026 and $3,950,000,000 USD for the six months ended June 27, 2026, versus $1,834,000,000 USD for the three months ended June 28, 2025 and $3,551,000,000 USD for the six months ended June 28, 2025. Both the three-month and six-month figures are profits and the authorized direction is higher than the prior period, with an authorized transition of profit to profit in each window.

- Bottom-line earnings followed the same shape. Net Income (Loss) Attributable to Parent was $1,736,000,000 USD for the three months ended June 27, 2026 and $3,387,000,000 USD for the six months ended June 27, 2026, against $1,617,000,000 USD for the three months ended June 28, 2025 and $3,124,000,000 USD for the six months ended June 28, 2025. The authorized direction is higher than the prior period on both windows, with an authorized transition of profit to profit.

26 per diluted share USD/SHARES for the six months ended June 28, 2025; both comparisons show higher than the prior period with an authorized transition of profit to profit. - On the sequential read, the three-month versus prior-year comparison carries the same direction as the year-to-date comparison, so there is no quarter-over-quarter tension that contradicts the year-over-year signal in revenue, operating income, net income, or diluted EPS. The quarter-over-quarter dimension is not separately reported in the reported comparison set, so any seasonality read beyond what the prior-year delta shows is not asserted here.

- The accounting context is unchanged: the interim statements are presented as permitted by 10-Q for THERMO FISHER SCIENTIFIC INC. (CIK 0000097745, accession 0000097745-26-000144, ticker TMO, fiscal period period-ended-2026-06-27) and are read alongside the annual report, with Note 1 describing the significant accounting estimates and policies and no material changes in those policies during the six months ended in the current period. Certain prior-year amounts were reclassified to conform to the current-year presentation, and totals may differ from the sum of components due to rounding of underlying unrounded amounts.

- Forward-looking standards: the company has adopted ASU improvements to income tax disclosures and is preparing for disaggregation-of-expenses, internal-use software, and government-grants pronouncements, none of which alters the recognized figures above. Backlog visibility is supported by the remaining performance obligations disclosed in Note 6, with a majority expected to be recognized within the next twelve months and the balance tied to longer-dated contract manufacturing, clinical research, and extended warranty arrangements.

- The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute these changes to any single cause, and no peer or industry comparison is provided in the filing. For context on how other interim filers have framed identical profit-to-profit patterns, see the Broadcom interim filing summary and the ONEOK interim filing summary.

Operating drivers and segments

The condensed consolidated statements presented in the filing for THERMO FISHER SCIENTIFIC INC. cover the company as a single reportable entity, with no separate operating-segment disaggregation of revenue or operating income in the quoted evidence. The only top-of-house figures available for an operating-driver read are Revenue from Contract with Customer, Excluding Assessed Tax and Operating Income (Loss). Revenue was $11,994,000,000 USD in the three months ended June 27, 2026, versus $10,855,000,000 USD in the three months ended June 28, 2025 — both positive, and the authorized direction is higher year over year. For the half-year window, Revenue was $22,999,000,000 USD in the six months ended June 27, 2026 versus $21,219,000,000 USD in the six months ended June 28, 2025 — also higher year over year on the authorized read. Operating Income (Loss) was $2,087,000,000 USD in the three months ended June 27, 2026 versus $1,834,000,000 USD in the three months ended June 28, 2025 — profit-to-profit on the authorized read with direction higher. The half-year operating income moved from $3,551,000,000 USD in the six months ended June 28, 2025 to $3,950,000,000 USD in the six months ended June 27, 2026 — again profit-to-profit and higher year over year on the authorized read. The filing evidence contains no peer or industry comparison. Management frames the business through the Nature of Operations language in Note 1, describing the company as enabling customers in life sciences research, complex analytical challenges, laboratory productivity, and patient health through diagnostics and the development and manufacture of therapies, serving pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics end-markets. The narrative quoted in the source material does not, in the excerpt available here, break revenue growth or operating income gains down by segment, geography, product family, or end-market, and it does not call out pricing, volume, mix, currency, or acquisition contributions. Management also discloses in Note 1 that remaining performance obligations as of the period-end balance sheet date totaled a stated amount expected to be recognized largely within the next twelve months, which is the only forward-looking operational data point quoted in this section.

The evidence available to this section cannot attribute the year-over-year gains in revenue or operating income to any single operating driver. The filing evidence does not attribute this change to any single cause. No segment-level revenue, segment-level operating income, or end-market split is presented in the quoted excerpts, so an independent segment-margin view cannot be constructed from the filing alone. Readers looking for a peer-anchored read on Thermo Fisher's quarterly operating performance can compare the company-level revenue and operating-income pattern against peer interim filings such as Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in the reporting period Filing, but the filing evidence itself contains no such peer comparison. The only remaining unknowns for this section are a segment split, any geographic or end-market attribution for the revenue and operating-income gains, and any management quantification of organic versus inorganic contribution across both windows.

Cash flow and capital

- Reported facts THERMO FISHER SCIENTIFIC INC. (the issuer identified by TMO under accession 0000097745-26-000144 for period-ended-2026-06-27 filed on 10-Q) presents a six-month year-to-date cash flow statement that frames the rest of the balance sheet story. Operating activities generated $3,317,000,000 for the six months ended June 27, 2026, compared with $2,122,000,000 for the six months ended June 28, 2025, with the authorized year-over-year direction reading as an increase on a positive base. Investing activities were a net outflow of -$8,797,000,000 in the current window versus -$815,000,000 in the prior year, with the authorized direction reading as a decrease on a negative base. Financing activities were a net outflow of -$478,000,000 for the six months ended June 27, 2026, compared with -$1,093,000,000 for the six months ended June 28, 2025, with the authorized direction reading as an increase on a negative base.

Inside that financing line, capital returns were heavier year over year. Payments for repurchase of common stock were $4,000,000,000 for the six months ended June 27, 2026, against $2,000,000,000 for the six months ended June 28, 2025, with the authorized direction reading as an increase on a positive base. Payments of ordinary dividends on common stock were $337,000,000 for the six months ended June 27, 2026, against $311,000,000 for the six months ended June 28, 2025, with the authorized direction reading as an increase on a positive base. Property, plant and equipment acquisitions were $826,000,000 for the six months ended June 27, 2026 and $656,000,000 for the six months ended June 28, 2025, with the authorized direction reading as an increase on a positive base.

On the balance sheet date the balance sheet date of June 27, 2026, the company carried $4,064,000,000 in cash and cash equivalents at carrying value, with accounts payable of $3,268,000,000 sitting on the other side of working capital.

- Management explanations Management's notes point to the funding sources behind those outflows. The cited note on debt and other financing arrangements describes a multi-currency revolving Facility with capacity up to a stated ceiling, alongside U.S. dollar and euro commercial paper programs with short-dated maturities, plus U.S. dollar, euro, Swiss franc and Japanese yen senior notes subject to customary covenants. Management states the company was in compliance with all senior note covenants at the period date.

- Analyst inference Operating cash was sufficient to cover capital returns and capex while leaving room for continued investing outflows, and the authorized year-over-year directions are consistent with a story of higher cash generation funding a larger share repurchase and dividend program. The authorized direction on investing is recorded as a decrease on a negative base, which means the outflow narrowed rather than grew.

- Counter-evidence Even with bigger buybacks and a higher dividend, financing remained a net use of cash, so the larger capital return program has not yet been fully funded out of new debt in this window.

- Unknowns The drivers behind the shift in the investing line are not separately attributed in the cited note. The filing evidence does not attribute this change to any single cause.

Peer and historical context

The three-month reporting period shows revenue moving from $10,855,000,000 USD in the prior-year quarter to $11,994,000,000 USD in the current quarter, with the authorization describing the move as an increase. Operating income tracked the same direction, climbing from $1,834,000,000 USD to $2,087,000,000 USD, and the bottom line followed in kind: net income attributable to parent moved from $1,617,000,000 USD to $1,736,000,000 USD, all of which the catalog records as a profit-to-profit transition. Read against filings that show a similar profit-to-profit arc on both windows — for example, the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing write-up and the ONEOK Posts Higher Revenue, Operating Income, Net Income and Diluted EPS Year-Over-Year in Interim Filing insight — Thermo Fisher's quarter sits in the same family of interim reports that posted gains on revenue, operating income and net income at the same time.

The six-month year-to-date window tells the same story at a wider scale. Revenue rose from $21,219,000,000 USD in the six months ended June 28, 2025 to $22,999,000,000 USD in the six months ended June 27, 2026 on an authorized increase, operating income moved from $3,551,000,000 USD to $3,950,000,000 USD on the same authorized direction, and net income attributable to parent climbed from $3,124,000,000 USD to $3,387,000,000 USD, again a profit-to-profit transition. Operating cash flow was also higher on a year-over-year basis, with the current $3,317,000,000 USD running above the prior-year $2,122,000,000 USD, an authorized increase from a positive base to a positive base. Comparable interim narratives can be seen in the Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows and the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows pieces, which describe the same dual-window shape. The filing evidence contains no peer or industry comparison.

The filing evidence does not attribute this change to any single cause.

Scenario analysis

The base case anchors on the reported figures as filed: THERMO FISHER SCIENTIFIC INC. posted revenue of $11,994,000,000 USD for the three months ended June 27, 2026, higher than the $10,855,000,000 USD booked in the three months ended June 28, 2025, alongside a net income attributable to parent of $1,736,000,000 USD versus $1,617,000,000 USD a year earlier. The year-to-date comparison mirrors that posture, with revenue at $22,999,000,000 USD against $21,219,000,000 USD for the six months ended June 28, 2025 and net income at $3,387,000,000 USD versus $3,124,000,000 USD. Both windows therefore carry authorized profit-to-profit transitions on the top and bottom lines. The base view treats this trajectory as the central tendency, supported by the senior notes covenant language in Note 3, which notes compliance at the balance-sheet date and a maintenance Consolidated Net Interest Coverage Ratio floor measured each fiscal quarter. Reported financial figures are presented in the issuer's own condensed consolidated statements; commentary on management's qualitative narrative sits apart from those audited numbers.

The constructive case leans on continued top-line expansion, with revenue of $11,994,000,000 USD for the three months ended June 27, 2026 outpacing $10,855,000,000 USD in the three months ended June 28, 2025, and the year-to-date reading of $22,999,000,000 USD above $21,219,000,000 USD. Bottom-line strength reinforces the picture, as net income of $1,736,000,000 USD exceeds $1,617,000,000 USD, and $3,387,000,000 USD exceeds $3,124,000,000 USD. The capital-structure commentary in Note 3 describes multi-currency commercial paper capacity, fixed and floating-rate senior notes, and a euro program with maturities capped in the cited note, all of which provide flexibility to fund working capital and investment without breaching the cited covenant. In a related setting, Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing illustrates how multi-window top-line and earnings momentum can be reinforced when covenant and liquidity headroom remain intact.

The cautious case still acknowledges the reported readings: revenue of $11,994,000,000 USD against $10,855,000,000 USD, and net income of $1,736,000,000 USD against $1,617,000,000 USD. The half-year readings of $22,999,000,000 USD versus $21,219,000,000 USD, and $3,387,000,000 USD versus $3,124,000,000 USD, frame the downside's starting point. Risk considerations emphasise the Consolidated Net Interest Coverage Ratio floor referenced in Note 3, the make-whole call protection on the dollar and euro-denominated fixed-rate senior notes, and the private placement notes' cross-currency swap breakage costs, which together raise the price of any rapid refinancing. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- The headline earnings metrics in the 10-Q filed by THERMO FISHER SCIENTIFIC INC. under 0000097745-26-000144 for the three months ended June 27, 2026 and the six months ended June 27, 2026 both moved in the same authorized direction year over year, but the filing itself does not separate organic growth from acquisitions, currency translation, or pricing actions on either window. Reported revenue of $11,994,000,000 for the three-month period compares with prior-year revenue of $10,855,000,000, and the year-to-date revenue of $22,999,000,000 compares with $21,219,000,000, so any commentary on quality of growth has to be flagged against that limit.

Reported net income for the three months was $1,736,000,000 versus $1,617,000,000, while the year-to-date figure was $3,387,000,000 versus $3,124,000,000, leaving a clear gap between the two windows worth watching next period. The filing evidence does not attribute this change to any single cause. - Counter-evidence worth holding in mind sits inside the company's own disclosures rather than in third-party sources.

The filing discusses covenant compliance on senior notes and a guarantee structure in which THERMO FISHER SCIENTIFIC INC. has fully and unconditionally guaranteed all of Thermo Fisher International's obligations under the Euronotes and other debt securities, with Thermo Fisher International defined as a "finance subsidiary" whose financial condition, results of operations and cash flows are consolidated into the parent. That structure makes the parent's reported earnings sensitive to financing arrangements captured in the cited note on debt and other financing, including the make-whole and swap-breakage cost language on certain euro-, Swiss franc-, Japanese yen- and dollar-denominated issuances.

Refinancing or rate-resetting in any of those currencies could therefore pull at reported results in ways not visible from the top-line numbers alone. The same cited note also describes affirmative and negative covenants, the most restrictive of which limits the company's ability to pledge certain property and assets as security under borrowing arrangements. - Unknowns that investors typically probe but that the filing evidence does not answer include segment-level performance, where The filing evidence does not disclose segment-level detail for this dimension.

applies, and any peer or industry benchmark for the period, where The filing evidence contains no peer or industry comparison. applies. The risk-factor and legal-proceedings discussion referenced under Item 1A is not reproduced in the source narrative, so any read on new versus carry-forward risks from those sections has to be set aside until the underlying filing is read directly.

Fair-value disclosures referenced under Level 1, Level 2 and Level 3 and the long-term borrowing fair-value note Note 4 are present as references but their numbers were stripped, so no inference about the lower fair-value tier or the initial liquefaction phase should be drawn from this article. - Metrics to watch next period include the three-month and six-month revenue lines against the prior comparatives in this filing, the corresponding net income and operating income transitions, and any change in the senior-notes coupon calendar or covenant disclosures in Note 3 that could reset interest expense.

Inventory composition referenced under Note 2 and the accounting policy basis referenced under Note 1 are also worth re-reading next quarter for any sign of a mix shift. For cross-company context, readers comparing quarter-over-quarter movements may find a parallel read in Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in the reporting period Filing useful, and the calculation framing in Calculate ROI for Investment Property: A Simple Method gives a complementary lens on return measurement when stress-testing the income line against capital deployed.